Sign inJoin waitlistJoin the waitlist

Brian Henick

Director, Experimental Therapeutics/Phase I Program, HICCC · HICCC

Credentials: · · · ·

History

Experimental Therapeutics/Phase I Program · HICCC
Present
ARIC at NYPH Milstein Hospital
Present
CUMC
Present

Research

Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression…
JAMA Oncology · 2022 · 327 citations
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
Annals of Oncology · 2019 · 326 citations
Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy
Clinical Cancer Research · 2020 · 282 citations

Catherine Shu
8 papers
KS
Kurt Schalper
8 papers
RH
Roy Herbst
8 papers
Adam Mor
7 papers
Anjali Saqi
7 papers
Benjamin Herzberg
6 papers
DR
David Rimm
6 papers
NR
Naiyer Rizvi
6 papers
Robert Winchester
6 papers
Gary Schwartz
5 papers
JG
Justin Gainor
5 papers
Mahesh Mansukhani
5 papers

Clinical trials

Brodalumab in the Treatment of Immune-Related Adverse Events
Principal investigator · Recruiting · Phase 1
Brian Henick, MD
2025–2027
Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients
Principal investigator · Terminated
Columbia University
2023–2025
Liver Directed RT + Chemo-immunotherapy for ES-SCLC
Principal investigator · Terminated · Phase 2
Brian Henick, MD
2021–2023
Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)
Principal investigator · Active not recruiting · Phase 2
Columbia University
2020–2026